December 23, 2022
Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium
Director, Cancer Discovery Hub, National Cancer Centre Singapore
Consultant, Division of Medical Oncology, National Cancer Centre Singapore
Deputy Director, Division of Medical Oncology Research, National Cancer Centre Singapore
Assistant Professor, Duke-NUS Medical School
Dr Jason Chan obtained his medical degree from the National University of Singapore and achieved his postgraduate accreditation from the Royal College of Physicians (UK). He completed specialist training at the National Cancer Centre Singapore and subsequently obtained a Doctorate from the Cancer Science Institute of Singapore.
His key research interests lie in unravelling the causes and molecular pathobiology of lymphomas and rare cancers with the aim of improving clinical care of patients inflicted with these diseases. Dr Chan is Principal Investigator of the STARLIGHT Initiative for Rare Cancer Research and Education. Additionally, he is Theme Principal Investigator for SYMPHONY (Singapore Lymphoma Translational Study) and Executive Committee member for TETRAD (TargEted TheRApy for blooD Cancer). He has contributed to major research efforts on Asian-prevalent lymphomas including NK/T-cell lymphomas and monomorphic epitheliotropic T-cell lymphoma, as well as breast fibroepithelial tumors, angiosarcomas, and liposarcomas. For these efforts, he was awarded the Nurturing Clinician Scientist Scheme by the SingHealth Duke-NUS Academic Medical Centre in 2017, Singapore National Medical Research Council (NMRC) Research Training Fellowship in 2018 and NMRC Transition Award in 2021. He is also a proud alumnus of the ESMO Leadership Generation Program in 2022.
Singapore Translational Cancer Consortium (STCC) has signed its first cross-border partnership with the Australian Victorian Cancer Biobank (VCB) to foster collaborations in translational oncology research. As part of the partnership agreement, STCC and VCB will share its oncology specimen databases, allowing researchers to access a wider array of tissue samples for cancer research. Both organisations will also share tissue banking best practices, and establish outreach programmes to advance clinical research collaborations between the two countries.
SINGAPORE - The development of mRNA-based cancer vaccines in Singapore is being funded by the Ministry of Health (MOH), as part of its support for “competitive cancer research projects” here, said Senior Minister of State for Health Janil Puthucheary.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).